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Abstract
Insomnia is reported to chronically affect 10,15% of the adult population. However, very little is known about the genetics
and metabolism of insomnia. Here we surveyed 10,038 Korean subjects whose genotypes have been previously profiled on
a genome-wide scale. About 16.5% reported insomnia and displayed distinct metabolic changes reflecting an increase in
insulin secretion, a higher risk of diabetes, and disrupted calcium signaling. Insomnia-associated genotypic differences were
highly concentrated within genes involved in neural function. The most significant SNPs resided in ROR1 and PLCB1, genes
known to be involved in bipolar disorder and schizophrenia, respectively. Putative enhancers, as indicated by the histone
mark H3K4me1, were discovered within both genes near the significant SNPs. In neuronal cells, the enhancers were bound
by PAX6, a neural transcription factor that is essential for central nervous system development. Open chromatin signatures
were found on the enhancers in human pancreas, a tissue where PAX6 is known to play a role in insulin secretion. In PLCB1,
CTCF was found to bind downstream of the enhancer and interact with PAX6, suggesting that it can probably inhibit gene
activation by PAX6. PLCB4, a circadian gene that is closely located downstream of PLCB1, was identified as a candidate
target gene. Hence, dysregulation of ROR1, PLCB1, or PLCB4 by PAX6 and CTCF may be one mechanism that links neural
and pancreatic dysfunction not only in insomnia but also in the relevant psychiatric disorders that are accompanied with
circadian rhythm disruption and metabolic syndrome.
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Introduction
Sleep is a complex physiological process. Genetic determinants
underlying sleep phenotypes have only recently begun to be
revealed. Reduced sleep has been associated with a mutation in
the transcription factor DEC2 in a family-based genetic study [1].
Several quantitative traits related to sleep, such as sleepiness, usual
bedtime, and sleep duration, have been examined in a genome-
wide association study for 749 subjects [2]. A common sleep
disorder, restless legs syndrome, has been characterized by
genome-wide association analyses for larger populations [3,4].
However, little is known about the genetic background of
insomnia, one of the most common sleep disorders, which affects
10,15% of the adult population. In a classic twin study [5],
.1,000 monozygotic twins and .800 dizygotic twins were
examined in terms of insomnia and sleepiness. Heritability was
estimated at 57% for insomnia and 38% for sleepiness.
Interestingly, obesity was also under strong genetic influence and
shared genetic effects were found between insomnia and obesity
[5]. However, the particular genetic contributions common to the
two phenotypes remain to be identified.
To study genetic and metabolic aspects of insomnia, we
employed the population dataset from the Korea Association
Resource (KARE) project. The Ansung and Ansan cohorts,
consisting of 5,018 and 5,020 participants ranging in age from 40
to 69 years, were investigated. A genome-wide association analysis
has been carried out based on the genotypes of the subjects [6]. In
addition, demographic information, medical history and health
conditions, family disease history, dietary intake, and lifestyle, were
examined as part of the Korean Genome Epidemiology Study
(KoGES) [7]. We focused on body composition, and biochemical
and anthropometric traits.
Results and Discussion
The blood cells of the 10,038 subjects were genotyped using the
Affymetrix Genome-Wide Human SNP array 5.0. We discarded
SNPs with a minor allele frequency ,0.01 or a Hardy-Weinberg
equilibrium P value ,10
26. Our quality control and filtering
criteria left 81,055 SNPs and 8,842 individuals. Sleeping behavior
was examined by questionnaires. The case and control groups
were identified based on their answers to questions as to overall
insomnia, onset insomnia (difficulty in falling asleep), middle
insomnia (difficulty in maintaining sleep or returning to sleep after
awakening in the middle of the night), and terminal insomnia
(early awakening in the morning). A total of 1,439 respondents
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18455reported to have overall insomnia, leaving 7,280 in the control
group and 123 in the non-response group. Genotypic differences
between the case and control were tested for association by logistic
regression analysis with the additive model after adjustment for
age and sex.
A subset of the insomniacs was able to specify their insomnia
type. About 78.9%, 81.0%, and 56.4% of the respondents
reported onset, middle, and terminal insomnia, respectively
(Figs. 1A–1C). Insomnia is known to be 1.4 times more common
in women than in men. Our survey confirms this tendency by
measuring 21.3% and 11.2% in women and men, respectively.
The percentage of those who have irregular sleeping time was
marginally higher among the insomniacs (Figure 1D). The
insomniacs were ,6.7 times more likely to have relied on medical
treatment (Figures 1E–1F). In addition, 21.1% and 26.3% of the
insomniacs complained of restless legs syndrome and periodic limb
movement disorder, respectively (Figures 1G–1H).
To observe the physiological phenotypes of insomnia, we
examined a total of 12 outputs of body composition analysis as
well as 67 biochemical and 41 anthropometric traits. Multiple
regression analysis was performed for each variable, controlling for
sex and age, to compare the insomniac and normal respondents.
A significantly lower body weight was observed with the
insomniacs (Table 1). Body composition analysis supported this,
showing lower skeletal muscle mass, total protein mass, and lean
body mass (body mass minus fat mass). The insomniacs displayed
decreased serum albumin and elevated levels of c-glutamyl
transferase (GGT), insulin, and triglyceride (Table 1). Low serum
albumin reflects hepatic dysfunction. Elevated serum GGT and
insulin levels can both indicate insulin resistance. In fact, increased
insulin secretion was interpreted as a consequence of higher insulin
resistance among insomniacs [8]. A higher proportion (8.9%) of
the insomniacs have been diagnosed with diabetes as compared to
6.5% of the normal subjects (p=0.00117). Insulin facilitates the
conversion of carbohydrates into fat and increases triglyceride
levels, which seems to result in the higher levels of obesity degree
(p=0.01730) among the insomniacs.
Besides the primary circadian clock in the brain, local biological
clocks are also found in tissues such as the pancreas and liver. A
recent study [9] showed that b cells in the pancreas have their own
clock that governs the rhythmic behavior of genes involved in
insulin secretion. The knockout of certain clock genes was shown
to inhibit insulin secretion and trigger the onset of diabetes [9]. In
this respect, the observed metabolic changes in insomnia may stem
from genetic problems that simultaneously affect the brain and
pancreatic circadian clock.
The insomniacs also displayed higher serum calcium (Table 1).
High serum calcium levels are associated with a faster decline in
cognitive function [10]. There is a strong correlation between
serum and brain calcium levels, owing to free diffusion across the
blood-brain barrier [11]. In fact, increased serum calcium leads to
calcium accumulation in rat brains [12]. Taken together, higher
calcium levels among the insomniacs may reflect a disruption of
neuronal calcium homeostasis. Calcium concentration is also
important in insulin release from pancreatic b cells [13]. Increased
serum calcium may be related to increased insulin levels.
We sought to find the underlying genetic causes of insomnia by
utilizing the previous genotype data [6]. Our association data for
insomnia has been made publicly available at author’s website
(http://compgen.kaist.ac.kr). All information pertaining to the
3354 SNPs identified at a marginal P-value cutoff (,0.005) is
given in Table S1. The name of the genes harbouring more than
10 significant SNPs is shown at the corresponding chromosomal
location of the Manhattan plot (Figure 2). Functional analysis of
the genes containing at least one of the SNPs showed a remarkable
enrichment for neural function (Table S2). For example, the top
two functional groups showed enrichments of synaptic genes and
another group contained many genes related to neuron differen-
tiation. This implies combinatorial effects of multiple weak genetic
determinants in shaping insomniac phenotypes.
The most significant genic SNP (rs11208305, P=5.6610
26) was
foundwithintheROR1gene.ROR1modulatesneuritegrowthand
synapse formation in complex with ROR2 [14]. ROR1 and ROR2
harbored 16 and 14 of the identified SNPs, respectively (Table S1
and Figure 2). The second significant SNP (rs718712,
P=8.5610
26) was located within the PLCB1 gene along with 16
other identified SNPs. PLCB1 functions via calcium signaling in
long-term depression(Figure S1)and long-term potentiation(Figure
S2). Both processes are involved in the molecular basis of learning
and memory. CACNA1A, GNAS, NOS3, and ADCY8 in calcium
signaling (Figure S3) also harbored a few of the insomniac SNPs.
The calcium channel CACNA1A is implicated in several
Figure 1. Percentages of sleepers who (A) have difficulty falling asleep, (B) wake up during the night and not be able to fall back
asleep, (C) wake up too early in the morning, (D) have irregular sleeping time, (E) have received sleep treatment, (F) have taken
sleeping medicine, (G) have the symptoms of restless legs syndrome, and (H) have experienced periodic limb movements during
sleep. White bars represent the normal and gray the insomniac group.
doi:10.1371/journal.pone.0018455.g001
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disorder [16]) and in diabetes as well [17].
The ROR1 promoter was identified to exert high genetic
background effects from a genome-wide association study of
bipolar disorder [18]. In our study, many SNPs with marginal P
values were found in the ROR1 promoter (Figure 3A and Figure
S4), including rs7552384 (P=7.4610
24), 2 kb upstream of the
transcription start site. PLCB1, a gene that has long been studied
with regard to schizophrenia [19,20], is reported to also affect
sleep-associated theta rhythms [20]. It is worth noting that bipolar
disorder and schizophrenia are commonly characterized and
genetically linked with each other by circadian rhythm disruption
[21,22,23,24]. It has been demonstrated in a large-scale
population-based study that these two disorders indeed share
common genetic causes [25]. Moreover, these psychiatric
disorders are accompanied with metabolic syndrome [26,27,28],
similar to what we have observed for insomnia.
We thus focused on the ROR1 and PLCB1 regions (Figure 3).
Because the most significant SNPs fell within introns, we
suspected a role for regulatory elements. Interestingly, the
ENCODE data from multiple cell lines predicted distinct
chromatin marks around these SNPs. The ROR1 SNPs flanked
a strong peak of H3K4me1 (Figure 4A) and the PLCB1 SNPs
resided near an H3K4me1 peak and two CTCF binding sites
(Figure 5A). H3K4me1, often with H3K27ac, is a chromatin
marker for enhancers [29]. CTCF is an insulator-binding element
that can interfere with nearby enhancers.
We experimentally detected H3K4me1 and CTCF in two
neuronal cell lines (Figures 4B and 5B). Interestingly, the
TRANSFAC database predicted multiple PAX6 and PAX4
binding sites within or near the H3K4me1 marks. PAX6 is
known to be coexpressed with PLCB1 and circadian clock genes in
the pineal gland [30]. We observed that PAX6 is expressed in one
of the two examined cell lines (SK-N-MC) and binds the predicted
enhancer of ROR1 (Figure 4B) and PLCB1 (Figures 5C). In the
other cell line (SH-SY5Y), there was no signal demonstrating
PAX6 binding to ROR1 even with the H3K4me1 mark (Figure
S5). We also found that PAX6 and CTCF were interacting across
the identified PLCB1 region. The PAX6 protein was detected in
the two CTCF sites, and CTCF was detected in the PAX6-bound
Figure 2. Manhattan plot for genetic association of insomnia. The name of the genes harboring more than 10 significant SNPs is shown at
the corresponding chromosomal position. The SNPs residing in these genes are shown as red dots.
doi:10.1371/journal.pone.0018455.g002





non-insomniacs t value Pr(.|t|)
Weight kg 60.463 63.646 23.509 0.00045
Skeletal muscle mass kg 40.777 44.201 23.407 0.00066
Total protein mass kg 10.889 11.801 23.368 0.00076
Lean body mass kg 43.255 46.821 23.321 0.00090
Serum albumin g/dL 4.176 4.261 23.393 0.00069
GGT IU/L 35.804 35.585 3.539 0.00040
Insulin mIU/mL 8.150 7.520 3.285 0.00103
Triglyceride mg/dL 167.657 161.845 2.991 0.00279
Ca
++ mg/dL 9.651 9.589 5.853 0.00000
doi:10.1371/journal.pone.0018455.t001
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Table S3.
What should be the regulation target of PAX6 and CTCF?
Which gene is activated by the enhancer and inhibited by the
insulators? The nearest promoter was found ,300 Kb down-
stream where the PLCB4 gene is located. Although it is also
possible that the PLCB1 gene itself is regulated by PAX6 and
CTCF, the fact that PLCB4 is directly related to circadian control
makes this gene a more likely candidate. PLCB4 is expressed in
tissues in the circadian entrainment pathway including suprachi-
asmatic nucleus. Based on the sleeping behaviors of PLCB4
knockout mice, it has been reported that this gene plays a role in
translating circadian oscillations of the molecular clock into
rhythmic outputs of suprachiasmatic nucleus neurons [31].
PAX6 plays a role at the interface of metabolism and neural
function. As a neuronal transcription factor that is essential for
central nervous system development [32], it also plays a role in
pancreatic development and insulin secretion [33]. In the pancreas,
it binds to the insulin promoter for activation [33]. We discovered
that the binding sites of PAX6 and CTCF in PLCB1 and ROR1
maintain openchromatinstructure in the human pancreas [34] (red
circles in Figures 4A and 5A). Therefore, it is possible that the
identified SNPsintheseregionscontributetoboth the circadianand
metabolic phenotypes of insomniacs.
Calcium signaling is important not only for learning and memory
in neurons but also for the exocytosis of insulin from pancreatic b
cells [13]. Many SNPs were embedded in calcium signaling
components, including PLCB1. APP, the precursor of b-amyloid,
is also known to stabilize intracellular free calcium levels (reviewed
in [35]). A recent report showed a connection between the sleep-
wake cycle and the pathogenesis of Alzheimer’s disease via b-
amyloid regulation [36]. APP was another gene bearing many
identified SNPs (Table S1). Surprisingly, the 12 SNPs in APP were
also located near H3K4me1 and H3K27ac. The enrichment of
H3K4me1 and H3K27ac was confirmed in neural cells (Figure S6).
To understand the effect of the regulatory SNPs in ROR1 and
PLCB1 in different sub-populations, we repeated our association
analysis within two subgroups of the population as divided by sex,
age, insulin level, or calcium level. Distinct differences were found
between male and female, and between high-insulin and low-
insulin groups.
Interestingly, the ROR1 SNPs were better associated with
female insomniacs (Table S4) while the PLCB1 SNPs with male
insomniacs (Table S5). Our previous association results were
obtained by using sex and age as a covariate, which means that
there is no genetic bias between different genders. Hence, a more
likely explanation is based on different degrees of penetrance; that
is, the insomniac genotypes in PLCB1 exhibit a higher degree of
penetrance in males while those in ROR1 are better expressed in
females. However, its mechanism remains unclear.
Also, the associations in ROR1 and PLCB1 were relatively better
pronounced in the low-insulin group (Tables S6–S7). There are two
Figure 3. P value plots, genomic structures and LD maps of (A) the ROR1 gene and (B) the PLCB1 gene. The –log10 of the association P
value of each SNP was plotted according to its chromosomal position. The gene structure was drawn at P=5610-3 with the vertical ticks indicating
exons, and the SNPs above this threshold were colored red (experimental) or orange (imputed) and those below it black (experimental) or gray
(imputed). The promoter region was attached to the ROR1 genebody to show the SNPs near the transcription start site. The LD maps based on D’
were drawn by Haploview using the genotype data of all cases.
doi:10.1371/journal.pone.0018455.g003
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18455Figure 4. Zoomed-in P value plot and chromatin signatures for the ROR1 region. (A) The vertical dotted lines indicate the DNA regions
selected for H3K4me1 and PAX6 ChIP PCR. Below is the UCSC Genome Browser screen for the corresponding region showing H3K4me1 and H3K27ac
in multiple cell lines. Open chromatin signatures in human pancreatic islets were employed from published data [34]. (B) The results of ChIP PCR for
H3K4me1 and PAX6 in the two regions. Input DNA and IgG antibody were used as positive and negative controls, respectively.
doi:10.1371/journal.pone.0018455.g004
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other genetic changes, which may also influence insulin secretion. It
is also possible that the normal in these groups have the same
genetic changes as the insomniacs but they do not express the
associated traits. Given that high insulin levels are often accompa-
nied with insomnia, it is likely that self-reported normal subjects in
these groups have potential to develop insomnia.
This is the first large-scale genome-wide association study of
sleeplessness that is supported by matched metabolic profiles.
Although a replication association study is required, our
association results are supported by the high relevance of the
identified genes and regulatory factors. First, we find that the
genotypic differences are highly concentrated in genes pertaining
to neuronal function. Second, the SNPs of interest were present in
the regions of high regulatory potential as predicted by public
epigenomic data and confirmed experimentally. Third, the
identified genes and regulatory factors could provide molecular
links to the relevant psychiatric disorders and the observed
metabolic signatures. Further studies on the detailed regulatory
mechanisms will shed new light on our understanding of insomnia.
Methods
Study Population
The population data used in this study are from the Korea
Association Resource (KARE) project that entailed a large-scale
genome-wide association analysis of 10,038 participants from two
regional cohorts. The Ansung and Ansan cohorts, consisting of
5018 and 5020 participants ranging in age from 40 to 69 years,
were investigated as part of the Korean Genome Epidemiology
Study (KoGES) [7]. More than 260 traits, including demographic
information, medical history and health conditions, family disease
history, dietary intake, and lifestyle, were extensively examined
through epidemiological surveys, physical examinations, and
laboratory tests as described, but here we focused on body
composition, and biochemical and anthropometric traits. Sleeping
patterns were surveyed based on questionnaires. Ethics committee
approval and written informed consent have already been
obtained in the KoGES [7] and are not required for the present
study. The information of the human participants was anony-
mously used in this study.
Genome-wide association analysis of case and control
groups
The blood cells of the 10,038 subjects were genotyped using the
Affymetrix Genome-Wide Human SNP array 5.0. The genotypes
from the Affymetrix arrays were determined using the BRLMM
algorithm [37]. Low quality SNPs were removed before the case-
control study for quality control (quality control method was
previously described [6]). In brief, we discarded SNPs with minor
allele frequency ,0.01 or a Hardy-Weinberg equilibrium P
value,10
26. The quality control and filtering criteria left out
81,055 SNPs and 8,842 individuals. The case and control groups
were identified based on their answers to questions as to overall
insomnia, onset insomnia, middle insomnia, and terminal
insomnia. A total of 1,439 respondents reported to have overall
insomnia, leaving 7,280 in the control group and 123 in the non-
response group. Genotypic differences between the case and
Figure 5. Zoomed-in P value plot and chromatin signatures for the PLCB1 region. (A) The dotted lines indicate the DNA regions selected
for H3K4me1, PAX6, and CTCF ChIP PCR. Below is the UCSC Genome Browser screen showing H3K4me1, H3K27ac, and CTCF. Corresponding open
chromatin [34] is shown. (B) The results of ChIP PCR for H3K4me1, PAX6, and CTCF. Input DNA and IgG were used as control. (C) Cross ChIP PCR
between PAX6 and CTCF. PAX6 ChIP DNA was detected in the two CTCF sites, and CTCF ChIP DNA was detected in the PAX6 site.
doi:10.1371/journal.pone.0018455.g005
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with the additive model after adjustment for sex and age. A
multivariate logistic regression model including sex and age as
covariates was implemented using the PLINK software package
[38]. The association results are available at http://compgen.kaist.
ac.kr/home/data.
Linkage disequilibrium
Linkage disequilibrium (LD) is the non-random association of
two or more loci on a chromosome with recombination between
them. The level of linkage disequilibrium is influenced by a
number of factors including genetic linkage, selection, the rate of
recombination, genetic drift, and population structure. To better
facilitate understanding of selected SNPs in disease association
studies, we identified common LD blocks in the context of the D’
and r(2) linkage disequilibrium. We used the Haploview software
(http://www.broadinstitute.org/haploview/) to infer the LD
structures in regions containing loci associated with insomnia risk.
D’=1 and LOD .2 were colored bright red.
SNP Imputation
The genotypes for missing markers in a data set can be
confidently inferred by LD and the correlation between genotypes
in a reference data set. Association tests of genotypic markers
should show similar levels of association compared with imputed
markers. We imputed missing SNPs by means of the PLINK
program [4] based on the E-M algorithm using the JPT/CHB
panel of HapMap reference. After SNP imputation, we included
the imputed SNPs for the association study.
Function and pathway analysis
Functional analysis of genes harboring identified SNPs was done
by using DAVID (http://david.abcc.ncifcrf.gov). The ‘Functional
Clustering’ function was used to group genes and functions with
related terms. The KEGG pathway database (http://www.
genome.jp/kegg/pathway.html) was used for the annotation of
identified genes.
Cell culture
Two different human neuroblastoma cell lines, SK-N-MC and
SH-SY5Y, were commercially obtained from ATCC (Rockville,
MD). Cells were grown in monolayer using DMEM medium
(Invitrogen, Carlsbad, CA, USA) and supplemented with 10%
fetal bovine serum. They were incubated at 37uCi n5 %C O 2 and
plated onto 175 mm culture plates.
Chromatin Immunoprecipitation and PCR
To investigate histone modification and transcription factor
binding, we performed chromatin immunoprecipitation (ChIP)
assays using a ChIP assay kit (Millipore, Billerica, MA, USA)
according to the manufacturer’s protocol. Briefly, formaldehyde
was added to culture medium at a final concentration of 1% for
10 min at 25uC, and crosslinking was stopped by incubating in
0.125 M glycine for 5 min. Cells were rinsed, sonicated on ice,
and pelleted by centrifugation; supernatant was then collected.
Lysates were incubated with Protein G beads with either 5 mgo f
H3K4me1 (ab8895; abcam), H3K4me3 (ab8580; abcam),
H3K27ac (ab4729; abcam), PAX6 (ab5790; abcam), CTCF
(ab70303; abcam) or IgG antibody, according to the manufactur-
er’s recommendations. They were rotated overnight at 4uC. Beads
were washed, treated with 50 mg proteinase K for 2 h at 55uC, and
cross-links were reversed overnight at 65uC. DNA was recovered,
ethanol precipitated with glycogen carrier, and resuspended in
10 ml water. PCR amplification was done using 1 ml of ChIP
DNA. For ChIP PCR, primers were designed using Primer3
software according to the following criteria: expected amplified
fragment size between 150 and 300 bp, primer size between 18
and 25 bases, and primer melting temperature (Tm) between 55
and 60uC. Reverse cross-linked chromatin prior to immunopre-
cipitation was used as a positive control (input) for PCR
amplification.
Supporting Information
Figure S1 Signaling pathway for long-term depression. The
genes identified in this study are marked by a red star, including
the PLC protein.
(PNG)
Figure S2 Signaling pathway for long-term potentiation. The
genes identified in this study are marked by a red star, including
the PLC protein.
(PNG)
Figure S3 Calcium signalling pathway. The pathway for long-
term depression. The genes identified in this study are marked by a
red star, including the PLCB gene.
(PNG)
Figure S4 P value plot and chromatin signatures for the ROR1
promoter. The –log10 of the association P value of each SNP was
plotted according to its chromosomal position. The gene structure
was drawn at P=5610-3 with the vertical ticks indicating exons,
and the SNPs above this threshold were colored red (experimental)
or orange (imputed) and those below it black (experimental) or
gray (imputed). Below is the UCSC Genome Browser screen for
the corresponding region showing H3K4me1, H3K27ac, and
H3K4me3 in multiple cell lines.
(PDF)
Figure S5 Same as Figure 4 except for the negative PAX6 ChIP-
PCR results when the PAX6(-) cell line was used.
(PDF)
Figure S6 P value plot and chromatin signatures for the APP
gene. (A–B) The dotted lines indicate the DNA regions selected for
H3K4me1, H3K4me3, and H3K27ac ChIP PCR. Below is the
UCSC Genome Browser screen showing H3K4me1, H3K27ac,
and corresponding open chromatin in pancreatic cells. (C) The
results of ChIP PCR for H3K4me1, H3K4me3, and H3K27ac.
Input DNA and IgG were used as controls.
(PDF)
Table S1 Statistical information pertaining to the 3354 SNPs
identified at the P-value cutoff of ,0.005.
(PDF)
Table S2 Functional analysis of the genes containing at least one
of the SNPs as an output of the ‘Functional Clustering’ function of
DAVID (http://david.abcc.ncifcrf.gov).
(PDF)
Table S3 Primer sequences used in ChIP-PCR.
(PDF)
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